Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Ganglioglioma
100%
Neoplasm
75%
Glioblastoma
66%
Brain Metastasis
55%
Magnetic Resonance Imaging
50%
Tumor
45%
Intracranial Tumor
42%
Functional Magnetic Resonance Imaging
36%
Stereotactic Radiosurgery
31%
Intraoperative MRI
28%
Cancer Surgery
27%
Overall Survival
26%
Awake Craniotomy
26%
Progression Free Survival
23%
Biopsy Technique
21%
DNA Template
18%
Diseases
17%
Radiation Necrosis
14%
Transcranial Magnetic Stimulation
14%
Radiation Therapy
14%
Karnofsky Performance Status
13%
Metastatic Carcinoma
13%
Tractography
13%
Recurrent Disease
12%
Chemotherapy
11%
Non Small Cell Lung Cancer
11%
Adjuvant Therapy
11%
Malignant Neoplasm
10%
Oligoastrocytoma
10%
Surgeon
9%
Radiosurgery
9%
Diffusion Tensor Imaging
9%
Epileptic Seizure
8%
Melanoma
8%
Clinical Imaging
8%
Tumor Recurrence
8%
Anatomical Concepts
7%
Preoperative Imaging
7%
Craniotomy
7%
Ventricle of Heart
7%
Morbidity
7%
Retrospective Study
7%
Genetics
7%
Conventional Imaging
6%
Neuronavigation
6%
Laser Surgery
6%
COVID-19
6%
Subependymoma
6%
Cell Density
6%
Brachytherapy
6%
Keyphrases
Tumor
62%
Photothermal Therapy
56%
Brain Metastases
47%
Glioma
45%
Resection
39%
Glioblastoma
37%
Stereotactic Radiosurgery
34%
Functional Magnetic Resonance Imaging
31%
Surgical Resection
24%
Intraoperative Magnetic Resonance Imaging (iMRI)
23%
Glioma Patients
23%
Gross Total Resection
20%
High-grade Glioma
20%
Transcranial Magnetic Stimulation
20%
Tumor Resection
19%
Cardiac Magnetic Resonance Imaging (cMRI)
18%
Progression-free Survival
17%
Overall Survival
17%
Extent of Resection
17%
Radiation Necrosis
17%
Single Institution
17%
Tumor Volume
16%
Awake Craniotomy
16%
Glioblastoma multiforme
14%
Recurrent Glioblastoma
13%
Karnofsky Performance Status
13%
Survival Prediction
13%
Brain Tumor
11%
Surgeons
11%
Intracranial Tumor
11%
Non-small Cell Lung Cancer (NSCLC)
11%
Navigated Transcranial Magnetic Stimulation (nTMS)
11%
Malignant Glioma
11%
Image Dataset
11%
Glioma Surgery
10%
Isocitrate Dehydrogenase 1 (IDH1)
10%
Chemotherapy
10%
Brain Tumor Patients
10%
Neurocognitive Function
10%
Tractography
9%
Local Control
9%
Rodent Brain
9%
Evans Blue
9%
High-field Intraoperative Magnetic Resonance Imaging
9%
Language Mapping
9%
Newly Diagnosed Glioblastoma
9%
Intraoperative Imaging
9%
Primary Brain Tumor
9%
Adjuvant Therapy
9%
Survival Outcomes
8%